Shareholders of Allot may be disgruntled due to the firm's poor recent performance and excessive CEO compensation. A review of executive pay could be on cards considering the sharp drop in EPS and investor loss over the past three years.
The stock's low P/S ratio, likely due to investors' doubt on robust revenue growth prospects and current conditions like declining revenues, could keep the share price low unless top-line growth substantially improves.
艾奥特通讯股票讨论区
$艾奥特通讯(ALLT.US)$ buy in 7.82 sell 12.25 after 8.23 the gaps are 9.76, 10.40, 11.34, 11.84 12.08.
$Synchronoss Technologies(SNCR.US)$ Buy in 1.59 sell 2.23.
$Puma Biotechnology(PBYI.US)$ buy in 2.72 sell 6.48.
$Avalo Therapeutics(AVTX.US)$ buy in .64. sell 1.76. Institutional investor has continued buying but the price may not have found bottom yet.
暂无评论